Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439084 · ClinicalTrials.gov registry record
COVID-19 in Patients With Chronic Liver Diseases
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 1,025
- Enrollment target
NCT04439084: Completed study, sponsored by Stanford University.
NCT04439084 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 1,025 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04439084 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 1,025 participants
- Enrollment target
Study Summary
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
Primary Outcome
Death due to any cause
Interventions
- OTHER Prospective Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,025 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2021-07-31 |
What the finished NCT04439084 record still lists
NCT04439084 is an observational study that tracks outcomes without assigning an intervention. Its 1,025 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Prospective Chart Review is the first listed.
NCT04439084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04439084 about?
NCT04439084 is a clinical study titled "COVID-19 in Patients With Chronic Liver Diseases". This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
What is the current status of trial NCT04439084?
This trial is currently completed. The enrollment target is 1,025 participants. The study started on 2020-03-06. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04439084?
The interventions under investigation include: Prospective Chart Review (OTHER).
Who is sponsoring clinical trial NCT04439084?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI